公开(公告)号：US11697646B2

公开(公告)日：2023-07-11

申请号：US17224161

申请日：2021-04-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yan Shi ,  Peter Tai Wah Cheng ,  Ying Wang ,  Jun Shi ,  Shiwei Tao ,  Jun Li ,  Lawrence J. Kennedy ,  Robert F. Kaltenbach, III ,  Hao Zhang ,  James R. Corte

IPC: C07D401/04 ,  C07D403/04 ,  C07D249/06 ,  A61P35/00 ,  A61P1/16 ,  A61P19/10 ,  A61P13/12 ,  A61P11/00 ,  C07C249/06 ,  C07C403/04

CPC classification number: C07D401/04 ,  A61P35/00 ,  C07C249/06 ,  C07C403/04 ,  C07D249/06 ,  C07D403/04 ,  A61P1/16 ,  A61P11/00 ,  A61P13/12 ,  A61P19/10

Abstract: The present invention provides compounds of Formula (I):




or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US11319309B2

公开(公告)日：2022-05-03

申请号：US16954552

申请日：2018-12-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yan Shi ,  Ying Wang ,  Peter Tai Wah Cheng

IPC: C07D413/12 ,  C07D413/14

Abstract: The present invention provides compounds of Formula (Ia) or (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US20200283430A1

公开(公告)日：2020-09-10

申请号：US16759660

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph E. Carpenter ,  Matthias Broekema ,  Jianxin Feng ,  Chunjian Liu ,  Wei Wang ,  Ying Wang

IPC: C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D487/04 ,  C07D471/04 ,  C07D519/00

Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20190185446A1

公开(公告)日：2019-06-20

申请号：US16223169

申请日：2018-12-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： YAN SHI ,  Peter Tai Wah Cheng ,  Ying Wang ,  Jun Shi ,  Shiwei Tao ,  Jun Li ,  Lawrence J. Kennedy ,  Robert F. Kaltenbach, III ,  Hao Zhang ,  James R. Corte

IPC: C07D401/04 ,  C07D403/04 ,  C07D249/06

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US20160016880A1

公开(公告)日：2016-01-21

申请号：US14774289

申请日：2014-03-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yan Shi ,  Peter T.W. Cheng ,  Ying Wang ,  Shung C. Wu ,  Hao Zhang

IPC: C07C59/13 ,  A61K31/415 ,  A61K31/192 ,  C07D307/79 ,  A61K31/343 ,  C07D333/56 ,  A61K31/381 ,  C07D271/06 ,  A61K31/4245 ,  C07C59/215 ,  C07C323/19 ,  C07C205/34 ,  C07D333/28 ,  C07D239/38 ,  A61K31/505 ,  C07D205/04 ,  A61K31/397 ,  A61K45/06 ,  C07D231/12

CPC classification number: C07C59/13 ,  A61K31/192 ,  A61K31/343 ,  A61K31/381 ,  A61K31/397 ,  A61K31/415 ,  A61K31/4245 ,  A61K31/505 ,  A61K45/06 ,  C07C43/192 ,  C07C43/196 ,  C07C47/277 ,  C07C59/215 ,  C07C59/72 ,  C07C62/34 ,  C07C69/675 ,  C07C69/708 ,  C07C69/732 ,  C07C69/734 ,  C07C69/736 ,  C07C69/757 ,  C07C69/76 ,  C07C205/34 ,  C07C235/26 ,  C07C237/22 ,  C07C311/51 ,  C07C323/19 ,  C07C2601/02 ,  C07C2602/08 ,  C07C2602/42 ,  C07D205/04 ,  C07D231/12 ,  C07D239/38 ,  C07D271/06 ,  C07D307/79 ,  C07D333/16 ,  C07D333/28 ,  C07D333/56

Abstract: The present invention provides compounds of Formula (I): (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.

Abstract translation: 本发明提供式（I）的化合物：（I）或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的GPR120G蛋白偶联受体调节剂。

公开(公告)号：US20220324829A1

公开(公告)日：2022-10-13

申请号：US17224161

申请日：2021-04-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： YAN SHI ,  Peter Tai Wah Cheng ,  Ying Wang ,  Jun Shi ,  Shiwei Tao ,  Jun Li ,  Lawrence J. Kennedy ,  Robert F. Kaltenbach, III ,  Hao Zhang ,  James R. Corte

IPC: C07D401/04 ,  C07D403/04 ,  C07D249/06 ,  A61P35/00 ,  C07C249/06 ,  C07C403/04

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US11370785B2

公开(公告)日：2022-06-28

申请号：US16759782

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph E. Carpenter ,  Jianxin Feng ,  Ji Jiang ,  Soong-Hoon Kim ,  Ying Wang ,  Gang Wu

IPC: C07D417/14 ,  C07D401/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D513/04

Abstract: The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US11168079B2

公开(公告)日：2021-11-09

申请号：US16759660

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph E. Carpenter ,  Matthias Broekema ,  Jianxin Feng ,  Chunjian Liu ,  Wei Wang ,  Ying Wang

IPC: C07D401/14 ,  A61K31/4545 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US11008300B2

公开(公告)日：2021-05-18

申请号：US16744303

申请日：2020-01-16

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yan Shi ,  Peter Tai Wah Cheng ,  Ying Wang ,  Jun Shi ,  Shiwei Tao ,  Jun Li ,  Lawrence J. Kennedy ,  Robert F. Kaltenbach, III ,  Hao Zhang ,  James R. Corte

IPC: C07D401/04 ,  C07D403/04 ,  C07D249/06 ,  A61P35/00 ,  A61P1/16 ,  A61P19/10 ,  A61P13/12 ,  A61P11/00 ,  C07C249/06 ,  C07C403/04

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US20210087178A1

公开(公告)日：2021-03-25

申请号：US16954325

申请日：2018-12-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yan Shi ,  Ying Wang ,  Peter Tai Wah Cheng ,  Jun Li ,  Steven J. Walker

IPC: C07D403/14 ,  C07D401/14 ,  C07D401/04

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.